Industry News

19 June 2025

Fresenius Kabi recalls Blood Administration Sets due to life-threatening risk

Fresenius Kabi has issued an urgent nationwide recall of a specific lot of its Ivenix Large-Volume Pump (LVP) Blood Products Administration Sets, following the discovery of a manufacturing defect that could lead to serious or even fatal consequences.
18 June 2025

Glenmark Pharmaceuticals receives five observations from USFDA following Monroe facility inspection

Glenmark Pharmaceuticals Ltd. has announced that the United States Food and Drug Administration (USFDA) has completed a Good Manufacturing Practices (GMP) inspection at its manufacturing facility in Monroe, North Carolina, USA.
16 June 2025

Bristol Myers Squibb expands radiopharmaceutical pipeline through RayzeBio–Philochem Partnership

The agreement grants RayzeBio exclusive worldwide rights to Philochem’s clinical-stage radiopharmaceutical candidate OncoACP3.
14 June 2025

Amneal receives USFDA Approval for Prednisolone Acetate Ophthalmic Suspension

Amneal Pharmaceuticals, Inc. announced the U.S. Food and Drug Administration (FDA) approval of prednisolone acetate ophthalmic suspension, 1% sterile which references Pred Forte.
13 June 2025

Apex Labs Granted Israel MoH Approval to Expand Phase 2b Macrodose Psilocybin PTSD Clinical Trial

Apex Labs Ltd. a pharmaceutical company transforming the standard of mental health care with psilocybin is pleased to announce the approval by the Israeli MoH and IRBs to open two additional clinical trial sites for SUMMIT-90.
13 June 2025

ORLADEYO® (berotralstat) approved in Colombia

BioCryst Pharmaceuticals, Inc. announced that the National Institute of Drug and Food Surveillance (INVIMA) in Colombia has granted approval for oral, once-daily ORLADEYO
12 June 2025

Bharat Biotech to advance GSKs Shigella vaccine candidate

Bharat Biotech International Limited (BBIL) has entered into a licensing agreement with GSK plc to take over the development of altSonflex1‑2‑3, GSK’s promising Shigella vaccine candidate.
12 June 2025

Fabhalta® demonstrates Significant Hemoglobin Improvement in New PNH Patient Population

Novartis announced promising results from its Phase IIIB APPULSE-PNH study, evaluating the twice-daily oral monotherapy Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria
11 June 2025

NVIDIA Partners With Novo Nordisk and DCAI to Advance Drug Discovery

NVIDIA announced a collaboration with Novo Nordisk to accelerate drug discovery efforts through innovative AI use cases. The work supports Novo Nordisk’s agreement with DCAI to use the Gefion sovereign AI supercomputer.
11 June 2025

Sun Pharma to Invest upto 25 Million USD in Pharmazz, Inc

Pharmazz, Inc. a late-stage biopharmaceutical company developing innovative therapies for unmet medical needs in critical care and neurology, has announced a 25 million USD equity investment from Sun Pharmaceutical Industries Limited